Due to the inability of NE/CAMPs to induce direct cytotoxicity against GBM cells, we hypothesized that the superior efficacy of NE/CAMP treatment may be due to the modulation of local and systemic anti‐tumor immune response. The gene discussed is CAMP; the disease is glioblastoma.